Exero Medical
Exero empowers health care providers with high-quality, actionable post-operative data directly from the surgical site that can save lives, improve patient prognosis, and reduce cost of care.
Problem & solution
Anastomotic leaks remain one of the most serious complications following colorectal surgery, often leading to extended hospitalization, reoperations, and increased mortality. Current detection methods rely on clinical signs or imaging after complications have already manifested, which can delay diagnosis until a patient’s condition has critically deteriorated
Primary customers & users
Hospitals and health systems purchase xBar, with decisions led by colorectal surgeons, surgical leadership, value analysis, supply chain, and procurement. Colorectal surgeons and OR teams use the system during surgery to manage and prevent postoperative complications.
Differentiation
xBar is a novel, minimally invasive solution designed to actively manage and prevent postoperative colorectal complications. Unlike conventional drains and passive monitoring, xBar provides targeted, controlled management at the surgical site, with the potential to improve outcomes while reducing complications, reinterventions, and hospital costs.
Current traction
Exero has achieved FDA Breakthrough Device designation for xBar and advanced the system through the FDA review process, with FDA feedback characterizing it as a minimal-risk product. The company is now preparing for commercialization, including hospital onboarding, surgeon adoption, market development, and launch planning ahead of anticipated FDA clearance.
How Summit participants can help
Introductions to U.S. health systems, colorectal surgery leaders, and hospital decision-makers would be most valuable, particularly early-adopter surgeons and IDNs. Connections to strategic healthcare investors, distribution partners, and Israeli medtech companies could also accelerate commercialization, clinical adoption, and market access.